This trial is active, not recruiting.

Condition non-hodgkin lymphoma
Treatment mor00208 (formerly xmab 5574)
Phase phase 2
Sponsor MorphoSys AG
Start date May 2013
End date November 2016
Trial size 120 participants
Trial identifier NCT01685008, 2012-002659-41, MOR208C201


This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory non-Hodgkin´s lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
mor00208 (formerly xmab 5574) MOR208

Primary Outcomes

Overall response rate (ORR)
time frame: 4 years

Secondary Outcomes

1. Patients response duration evaluation by hematology, bone marrow aspirated or biopsy, CT
time frame: bi monthly, up to 48 months
2. Safety will be evaluated by assessing adverse events, clinical lab data and vital signs, ECG, physical exam
time frame: weekly, up to 4 years
3. Pharmacokinetics of MOR00208 (Pharmacokinetic assessment comprises: Cmax, tmax, t1/2, CL
time frame: weekly, up to 12 weeks; 0, 1, 4, 24 hours post dose
4. Number of patients who develop anti-MOR00208 antibodies as a measure of immunogenicity
time frame: monthly up to 4 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. male or female patients ≥ 18 years of age. 2. histologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas : 1. FL 2. MCL 3. DLBCL 4. Other indolent NHL (eg, MZL/MALT) 3. Patients' NHL must have progressed after at least 1 prior rituximab containing regimen. 4. one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm, Exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled. 5. Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery 6. discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration. 7. off rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment. 8. Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria) 9. Life expectancy of > 3 months. 10. ECOG performance status of < 3. 11. laboratory criteria at screening: 1. Absolute neutrophil count (ANC) ≥ 1.0 (1000/mm3) 2. Platelet count ≥ 75 × 109/L without previous transfusion within 10 days of first study drug administration 3. Haemoglobin ≥ 8.0 g/dL (may have been transfused) 4. Serum creatinine < 2.0 x upper limit of normal (ULN) 5. Total bilirubin ≤ 2.0 × ULN 6. Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. 12. If a female of childbearing potential, a negative pregnancy test must be confirmed before enrolment and use of double-barrier contraception, oral contraceptive plus barrier contraceptive, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation. 13. If a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential. 14. able to comply with all study-related procedures, medication use, and evaluations. 15. able understand and give written informed consent and comply with the study protocol. Exclusion Criteria: 1. Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy. 2. Treatment with a systemic investigational agent within 28 days before the screening visit. 3. Previous treatment with an anti-CD19 antibody or fragments 4. Previous allogenic stem cell transplantation. 5. Known or suspected hypersensitivity to the excipients contained in the study drug formulation. 6. Clinically significant cardiovascular disease or cardiac insufficiency,cardiomyopathy, preexisting clinically significant arrhythmia, acute myocardial infarction within 3 months of enrolment, angina pectoris within 3 months of enrolment. 7. Clinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of HIV infection. 9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration. 10. Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent). 11. Major surgery or radiation therapy within 4 weeks before first study drug administration. 12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion. 13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis. 14. Active treatment/chemotherapy for another primary malignancy within the past 5 years 15. Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control. 16. History of noncompliance to medical regimens or patients who are considered potentially unreliable not cooperative

Additional Information

Official title A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkin´s Lymphoma (NHL)
Principal investigator Kristi Blum, MD
Trial information was received from ClinicalTrials.gov and was last updated in January 2015.
Information provided to ClinicalTrials.gov by MorphoSys AG.